Ovarian cancer is one of the most lethal gynecological cancers in the world, and its incidence is increasing gradually in Asian countries as a consequence of demographic factors and lifestyle changes. Ovarian cancer epidemiology, risk factor profiles, treatment aspects, and challenges may vary significantly between Asian countries. Hence, this study aims to summarize the current evidence on these topics in Asia including gaps which need stratified healthcare responses. A thorough literature search was performed on PubMed, Scopus and Web of Science for studies published between the years 2000 to 2023. Eligibility criteria Studies conducted on ovarian cancer in Asian populations (incidence, mortality and treatment disparities). Regional differences were observed in risk determinants, methods of diagnosis, and access to treatment based on results from a health-related quality of life analysis. In 2020, 40.5% (125,629/310,991) of global cases of ovarian cancer were from Asia with China (6.6 per 100000) and India (4.9 per 100000) contributing a large burden to the disease. Industrialized countries have a much more reported higher incidence rate as Japan (ASR 8.5) and Singapore (ASR 9.0), which is also due to change in lifestyle and availability of medical treatment. Frequent risk factors are BRCA1/2 mutations, advanced maternal age, and rising obesity. Poor access to healthcare causes patients in many low-income regions to be diagnosed with their illness only at later stages, and rural areas may lack further treatment options. As promising as the new molecular diagnostics and novel targeted therapies are, they will largely remain unavailable in world-wide resource–limited settings. Phase I and II studies of a novel olaparib-based regimen following first-line chemotherapy for advanced ovarian cancer in Asia show promising efficacy with manageable adverse events; however, further improvement is needed for public health initiatives towards early detection, genetic testing offering access to treatment and equitable access to evidence-based medicine.